DNLI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DNLI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Denali Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.353. Denali Therapeutics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2024-03-29), Denali Therapeutics's share price is $20.50. Denali Therapeutics's Median PS Value is $0.00. Therefore, Denali Therapeutics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Denali Therapeutics's Median PS Value or its related term are showing as below:
The historical data trend for Denali Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Denali Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's Price-to-Median-PS-Value falls into.
Denali Therapeutics's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 2.353 | * | 0 | |
= | 0.00 |
10-Year Median PS Ratio is 0.
Denali Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.353.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (NAS:DNLI) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Denali Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 20.50 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Denali Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Vicki L Sato | director | 940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
Carole Ho | officer: Chief Medical Officer | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Ryan J. Watts | director, officer: President and CEO | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Steve E. Krognes | officer: CFO and Treasurer | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Alexander O. Schuth | officer: COO and Secretary | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Marc Tessier-lavigne | director | 1 DNA WAY, SOUTH SAN FRANCISCO CA 94080 |
Erik Harris | director | 60 LEVERONI COURT, NOVATO CA 94949 |
Douglas K Bratton | 10 percent owner | 201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102 |
Nancy Thornberry | director | SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036 |
David P Schenkein | director | C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Biogen Inc. | 10 percent owner | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Biogen Ma Inc. | 10 percent owner | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
Arch Venture Partners Viii, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Partners Viii, Llc | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Fund Viii, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
From GuruFocus
By GuruFocusNews 06-15-2022
By GlobeNewswire 10-20-2022
By PRNewswire 06-21-2023
By sperokesalga 04-12-2023
By Ds*** 08-31-2022
By Value_Insider 10-20-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.